StockData
Neuraxis, INC logo

Neuraxis, INC (NRXS) stock

NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 0/30
$4.61−0.19 (-3.96%)

Close on Nov 17, 2026Market cap $57.89MP/E –Yield –

Neuraxis r&d expenses

Research and development expenses are spending on new products and technology.

Neuraxis's R&D Expenses for the twelve months ending Jun 30, 2026 was $650.94K, up 30.8% year over year. For fiscal 2025 it was $493.61K, up 13.8% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$493.61K+13.8%
FY2024Dec 31, 2024$433.61K+156.1%
FY2023Dec 31, 2023$169.32K-25.0%
FY2022Dec 31, 2022$225.61K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$274.34K+138.2%
Q1 FY2026Mar 31, 2026$99.57K-15.5%
Q4 FY2025Dec 31, 2025$146.18K+5.6%
Q3 FY2025Sep 30, 2025$130.85K+3.6%
Q2 FY2025Jun 30, 2025$115.20K+112.1%
Q1 FY2025Mar 31, 2025$117.87K+2016.1%
Q4 FY2024Dec 31, 2024$138.43K+208.0%
Q3 FY2024Sep 30, 2024$126.25K+15.0%
Q2 FY2024Jun 30, 2024$54.31K+223.3%
Q1 FY2024Mar 31, 2024$5.57K-93.2%
Q3 FY2023Sep 30, 2023$44.95K-47.8%
Q2 FY2023Jun 30, 2023$109.79K+703.4%
Q1 FY2023Mar 31, 2023$16.80K–
Q4 FY2022Dec 31, 2022$81.37K–
Q3 FY2022Sep 30, 2022$86.18K–
Q2 FY2022Jun 30, 2022$13.67K–

More Neuraxis figures

See a number that looks wrong?